In these activities, two experts on endometrial cancer discuss immune checkpoint inhibitors, including therapeutic rationale and their safety and efficacy as single agents and in combination therapies. Other topics of discussion include patient selection, toxicities, toxicity management, and how new therapies are entering into the clinical domain with increasing frequency.
In this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of the key data on combination therapies as well as associated adverse events and how to handle them. Visit www.MorningCommutePodcast.com/Endometrial5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
In this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting. Visit www.MorningCommutePodcast.com/Endometrial4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
In this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help determine patient treatment plans? Visit www.MorningCommutePodcast.com/Endometrial3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
In this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clinical level and share some patient cases. You don't want to miss these clinical pearls. Visit http://www.MorningCommutePodcast.com/CRC3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast cancer, but now it is also a target in some colorectal cancers. Dr. John Marshall and Dr. Sunni Kim take a look at some of the recent clinical data on the investigational therapies targeting HER2-positive colorectal cancer. Visit http://www.MorningCommutePodcast.com/CRC2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer? Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to incorporate these tests into clinical practice. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the groundbreaking PATHFINDER study that so far is showing impressive data. Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can one blood sample provide accurate screening for many cancers? Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. They also tackle the topic of disparities in care for patients with ovarian cancer and how clinical trials can address this. Visit http://www.MorningCommutePodcast.com/OvarianCancer3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes? Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
What is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-part series on PARP inhibitors and ovarian cancer. Visit http://www.MorningCommutePodcast.com/OvarianCancer1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options, the paradigm is shifting and that's good news. Visit http://www.MorningCommutePodcast.com/BCell3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
What are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our faculty look at key trial data as well as treatment management for this disease. Visit http://www.MorningCommutePodcast.com/BCell2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new antibody-based therapies in relapsed/refractory disease. Visit http://www.MorningCommutePodcast.com/BCell1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this final episode, our faculty discuss clinical trials that are in progress, the importance of the clinical trial process, and how they benefit patients and help move the needle on new and promising treatments. Visit http://www.MorningCommutePodcast.com/FL6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast, our faculty discuss the major classes of treatment for follicular lymphoma, including outcomes and managing the expected toxicities. Visit http://www.MorningCommutePodcast.com/FL5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
How is the best way to select and sequence follicular lymphoma therapies? In this episode, our faculty discuss this and more. Visit http://www.MorningCommutePodcast.com/FL4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In our third podcast in this series, our faculty take a look at third-line treatment options for follicular lymphoma patients. Visit http://www.MorningCommutePodcast.com/FL3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this second podcast of our series, our faculty continue their discussion of follicular lymphoma and its treatment, particularly for those patients who progress within the first 24 months, the progression of disease within 2 years (POD24). What is known about predictors of progression and what is the best path forward for these poor prognosis patients? Visit http://www.MorningCommutePodcast.com/FL2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
What are the initial treatment strategies for the newly diagnosed patient with follicular lymphoma? Our faculty discuss this and more in this first episode of our series on follicular lymphoma. Visit www.MorningCommutePodcast.com/FL1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
There is some good news for preventing and treating Covid in patients with chronic lymphocytic leukemia (CLL). New treatment advances allow clinicians to have a more balanced focus on CLL standards of care with Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and anti-CD20 treatments such as rituximab, and not as much worry about Covid. Visit journalclubpodcasts.com/CLLCovid2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
As with any treatment, toxicities can be a concern. Our faculty return to discuss toxicities with third-generation tyrosine kinase inhibitors. How can these toxicities be mitigated? How can you maximize benefit and minimize risks? Visit http://www.morningcommutepodcast.com/CML5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
What are the treatment response benchmarks when treating chronic myeloid leukemia and when, if ever, should therapies be switched? Moreover, how do you know if they are working? Our faculty discuss these questions and more. Visit http://www.morningcommutepodcast.com/CML4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
When treating patients with chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors, what is the optimal dose? Our faculty discuss this as well as treatment duration and other considerations for using these third-generation therapies. Visit http://www.morningcommutepodcast.com/CML3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast our faculty return for a discussion of a new target for the treatment of chronic myeloid leukemia and the newest treatment on the block, asciminib. Visit http://www.morningcommutepodcast.com/CML2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Third-line treatment of chronic myeloid leukemia and in particular BCR-ABL1 tyrosine kinase inhibitors are the latest therapeutics in the clinician's toolbox. In this podcast, our faculty discuss these treatments and which patients can derive the most benefit from them. Visit http://www.morningcommutepodcast.com/CML1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
How is the Covid-19 pandemic affecting patients with chronic lymphocytic leukemia (CLL)? Our faculty discuss several papers during this podcast that address the efficacy of CLL treatments, especially Bruton's tyrosine kinase inhibitors, on CLL as well as vaccine response in the treatment decisions for this patient population. Visit http://www.journalclubpodcasts.com/CLLCovid1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time? Visit http://morningcommutepodcast.com/nsclc6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faculty takes a look at PD-L1 expression and immunotherapies. Who are the best candidates for these therapies? Who should not receive them? Visit http://morningcommutepodcast.com/nsclc5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faulty discuss molecular testing for non-small cell lung cancer (NSCLC). Should all patients with NSCLC be tested for biomarkers? Visit http://morningcommutepodcast.com/nsclc4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this episode our faculty discuss clinical trials in oncology. Are they reflective of the general population of patients who will ultimately be affected by the trial outcomes? What are the factors that impact clinical trial demographics? Visit www.morningcommutepodcast.com/disparities5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this episode, our faculty continues their discussion about disparities in oncology care. Is there a solution? How can being team-focused help patients in their cancer care journey? Visit www.morningcommutepodcast.com/disparities4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
How does implicit bias impact patient care? What is unconscious bias and how can clinicians become more aware of their own biases is regard to patient care? Our faculty tackles these topics in this episode. Visit www.morningcommutepodcast.com/disparities3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
In this episode our faculty will focus on health equity. What causes health inequity? Is it lack of access to care, cancer screenings, early diagnoses? How does socioeconomic variables factor in? These questions and more will be discussed in this podcast. Visit www.morningcommutepodcast.com/disparities2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
In this episode, our faculty discuss disparities in oncology care. What exactly are health disparities? What populations are most at risk for experiencing disparities in care? Visit www.morningcommutepodcast.com/disparities1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
In this podcast our faculty discuss gastrointestinal (GI) cancers and antibody-drug conjugates. How are these new therapies changing the landscape of GI cancer care? Visit www.morningcommutepodcast.com/solidtumors6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
HER2 expression in gastric/gastroesophageal junction and colorectal cancer potentially paves the way for the use of targeted therapies for these cancers. Our faculty discuss these important clinical developments. Visit www.morningcommutepodcast.com/solidtumors5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies. Visit www.morningcommutepodcast.com/solidtumors4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.
Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time? Visit www.morningcommutepodcast.com/solidtumors3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faculty continue their discussion of antibody-drug conjugates. They look beyond targeting HER2 and review data on the treatment of metastatic triple-negative breast cancer, HER2 Low expressing breast cancer, and the emerging data on TROP2 and HER3 as new targets for therapy. Visit www.morningcommutepodcast.com/solidtumors2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Our faculty discuss the exciting developments in antibody-drug conjugate therapy for human epidermal growth factor receptor 2-positive breast cancer. Visit www.morningcommutepodcast.com/solidtumors1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit
Visit http://morningcommutepodcast.com/multiplemyeloma6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij and Dr. Thomas Martin will discuss the many treatments for multiple myeloma with a look at how to use them to manage the disease and derive maximum benefit for this patient population. What are some common side effects and how are they managed?
Visit http://morningcommutepodcast.com/multiplemyeloma5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij and Dr. Thomas Martin will discuss some of the new and emerging therapies for the treatment of triple-class refractory multiple myeloma in a rapid-fire discussion that you won't want to miss.
Visit http://morningcommutepodcast.com/multiplemyeloma4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. Ravi Vij and Dr. Thomas Martin discuss the growing excitement around chimeric antigen receptor T-cell, or CAR-T, therapies that target B-cell maturation antigen, or BCMA, for the treatment of multiple myeloma.
Visit http://morningcommutepodcast.com/multiplemyeloma3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. Ravi Vij and Dr. Thomas Martin take a look at one of the newest drugs for the treatment of multiple myeloma, the just-approved melflufen. They discuss the clinical data that led to its approval and the patients for whom it may show benefit.
Visit http://morningcommutepodcast.com/multiplemyeloma2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij, and Dr. Thomas Martin take a look at selinexor, isatuximab, and belantamab and how these are fitting in with current clinical practice.
Visit http://morningcommutepodcast.com/MultipleMyeloma1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Rvi Vij and Dr. Thomas Martin will discuss treatment of multiple myeloma in patients who have relapsed. Most of these patients are on maintenance therapy, so how do you select the right regimen for them? The good news is that there are many from which to choose.
Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations. At the time this podcast was recorded, cemiplimab was pending approval.
Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts discuss PD-L1 levels, do they matter, as well as choosing the best candidates for Immune checkpoint inhibitor therapy not combined with chemotherapy, and they will also touch on recognizing adverse events.
Visit MorningCommutePodcast.com/NSCLC1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode our experts discuss the current standards of care regarding patient work-up, diagnosis, as well as PD-L1 expression and emerging immunotherapy biomarkers in treatment selection for non-small cell lung cancer.
© 2020-2025 Ivy Podcast Discovery LLC
